KRAS Mutation Does Not Influence Atezolizumab Response in NSCLC
This retrospective analysis of the IMpower150 trial (NCT02486718) explored efficacy endpoints...
Read More
Dissemination (Meeting Coverage)
Adding Pembrolizumab to Perioperative Chemotherapy Improves Event-Free Survival in Early-Stage NSCLC
In KEYNOTE-671, neoadjuvant pembrolizumab plus chemotherapy followed by surgery and adjuvant...
Read More
What Can Real-World Evidence Teach Us About Atezolizumab Plus Bevacizumab in HCC?
Therapy with atezolizumab and bevacizumab improved recurrence-free survival in patients with...
Read More
IMbrave050: Adjuvant Atezolizumab Plus Bevacizumab Provides Landmark Recurrence-Free Survival for HCC
Adjuvant therapy with atezolizumab and bevacizumab improved recurrence-free survival in patients...
Read More
Cortical Excitation/Inhibition Imbalance Has Predictive Value in MS
In MS, a lower cortical imbalance between excitation and inhibition may serve as a predictive...
Read More
Two Dietary Interventions Lead to Improvements in MS-Related Disability
It is recommended that neurologists discuss the benefits of improving diet quality with their...
Read More
Effects on Patient with HCC on Aspirin During In-Hospital Outcomes
Although new immunotherapies have been used, hepatocellular carcinoma (HCC) still presents a low...
Read More
Analyzing Adjuvant Atezo+Bev Vs. Active Surveillance in HCC Patients
In the IMbrave050 study, the combination of adjuvant atezo (atezolizumab) and bev (bevacizumab)...
Read More
Use of Atezolizumab and Bevacizumab to Treat Advanced HCC
In recent years, significant progress has been made in treating advanced unresectable...
Read More
Utilizing Genomic Features and Protein Markers for MRD Detection in HCC Patients
Many researchers determined that the clinical significance of circulating tumor DNA (ctDNA) in...
Read More
Impacting OS in Patients with Unresectable HCC with 1L TIS
Tislelizumab (TIS) is a specific monoclonal antibody targeting programmed cell death protein 1...
Read More
Adjuvant Atezolizumab Impact on Recurrence Prevention and Cost Reduction in Early PD-L1 High NSCLC
Recurrent cases of non-small cell lung cancer (NSCLC) following surgery are common and carry...
Read More
Race and Curative-Intent Treatment Linked To Mortality Outcomes in Early-Stage NSCLC
In recent decades, persistent disparities in the survival of individuals with early-stage...
Read More
New Blood-Based RNA Platform for Early Lung Cancer Diagnosis
Blood-based methods utilizing circulating tumor DNA (ctDNA) and cell-free DNA (cfDNA) are...
Read More
CtDNA as Outcome Predictor in NSCLC Undergoing Targeted Therapies: A Meta-Analysis
For treating non-small cell lung cancer (NSCLC), liquid biopsy (LB) was analyzed using...
Read More
Adjuvant Chemotherapy in High-Risk, Early-Stage NSCLC with Clinical and Pathologic Features Reevaluated
Surgical resection is the preferred treatment for early-stage non-small cell lung cancer (NSCLC),...
Read More
FOF and Concern of Falling in Patients with Relapsing-Remitting or Progressive MS
Frequent falls and the fear of falling (FOF) are significant challenges experienced by individuals...
Read More
Mindfulness-Based Stress Reduction in MS: Correlates of Patient-Reported Outcomes and MRI Findings
Researchers conducted a study to examine the effects of mindfulness-based stress reduction (MBSR)...
Read More
Low-Fat Diet Trial: Assessing Fatigue in Multiple Sclerosis
Fatigue is a common and debilitating symptom among individuals with multiple sclerosis (MS)....
Read More
Pharmacological Comparison of Tolebrutinib with Other BTK Inhibitor Candidates for MS Treatment
Tolebrutinib, a covalent inhibitor of Bruton tyrosine kinase (BTK), has been specifically...
Read More